The ratio of CD8 T lymphocytes to macrophages was higher in pCR patients than in non‐PCR patients, and patients with a higher ratio of CD8 T lymphocytes to macrophages had a higher response rate, which indicated that TNBC patients with immune‐activated tumor microenvironments could benefit more from chemotherapy. This evidence concerns the gene CD8A and neoplasm.